Biopolym. Cell. 2008; 24(3):260-266.
Short Communications
6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase mRNA expression in streptozotocin-diabetic rats
1Mykhalchenko V. G., 2Tsuchihara K., 1Minchenko D. O., 2Esumi H., 3Prystupiuk O. M., 1Minchenko O. H.
- Palladin Institute of Biochemistry, NAS of Ukraine
9, Leontovycha Str., Kyiv, Ukraine, 01601 - National Cancer Center Hospital East
6-5-1 Kashiwanoha, Kashiwa-shi, Chiba 277-8577, Japan - Bogomoletz Institute of Physiology, NAS of Ukraine
4, Bogomolets Str., Kyiv, Ukraine, 01024
Abstract
We have determined that changes in the expression of 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase mRNA in streptozotocin-diabetic rats vary in different organs. The expression of different splice variants of PFKFB-3 mRNA is organ specific and changes in diabetes. We have identified new splice variant of PFKFB-3 mRNA which has catalytic domains identical to those of the main isoform and other alternative splice variants of PFKFB-3 but differs by the length of C-terminus. Results of this investigation support possible role of PFKFB-3 isozymes in adaptation of the cells to disordered carbohydrate metabolism resulting from the insulin deficiency.
Keywords: PFKFB-3 mRNA, alternative splicing, streptozotocin-diabetes, rats
Full text: (PDF, in English) (PDF, in Ukrainian)
References
[1]
Rider MH, Bertrand L, Vertommen D, Michels PA, Rousseau GG, Hue L. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. Biochem J. 2004;381(Pt 3):561-79.
[2]
Bando H, Atsumi T, Nishio T, Niwa H, Mishima S, Shimizu C, Yoshioka N, Bucala R, Koike T. Phosphorylation of the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase/PFKFB3 family of glycolytic regulators in human cancer. Clin Cancer Res. 2005;11(16):5784-92.
[3]
Chesney J. 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis. Curr Opin Clin Nutr Metab Care. 2006;9(5):535-9.
[4]
Atsumi T, Nishio T, Niwa H, Takeuchi J, Bando H, Shimizu C, Yoshioka N, Bucala R, Koike T. Expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase/PFKFB3 isoforms in adipocytes and their potential role in glycolytic regulation. Diabetes. 2005;54(12):3349-57.
[5]
Wu C, Khan SA, Peng LJ, Li H, Carmella SG, Lange AJ. Perturbation of glucose flux in the liver by decreasing F26P2 levels causes hepatic insulin resistance and hyperglycemia. Am J Physiol Endocrinol Metab. 2006;291(3):E536-43.
[6]
Wu C, Okar DA, Newgard CB, Lange AJ. Increasing fructose 2,6-bisphosphate overcomes hepatic insulin resistance of type 2 diabetes. Am J Physiol Endocrinol Metab. 2002;282(1):E38-45.
[7]
Rousseau GG, Hue L. Mammalian 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: a bifunctional enzyme that controls glycolysis. Prog Nucleic Acid Res Mol Biol. 1993;45:99-127.
[8]
Okar DA, Manzano A, Navarro-Sabate A, Riera L, Bartrons R, Lange AJ. PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. Trends Biochem Sci. 2001;26(1):30-5.
[9]
Okar DA, Lange AJ. Fructose-2,6-bisphosphate and control of carbohydrate metabolism in eukaryotes. Biofactors. 1999;10(1):1-14.
[10]
Kawaguchi T, Veech RL, Uyeda K. Regulation of energy metabolism in macrophages during hypoxia. Roles of fructose 2,6-bisphosphate and ribose 1,5-bisphosphate. J Biol Chem. 2001;276(30):28554-61.
[11]
Minchenko A, Leshchinsky I, Opentanova I, Sang N, Srinivas V, Armstead V, Caro J. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem. 2002;277(8):6183-7.
[12]
Minchenko O, Opentanova I, Minchenko D, Ogura T, Esumi H. Hypoxia induces transcription of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase-4 gene via hypoxia-inducible factor-1alpha activation. FEBS Lett. 2004;576(1-2):14-20.
[13]
Hopfl G, Ogunshola O, Gassmann M. HIFs and tumors--causes and consequences. Am J Physiol Regul Integr Comp Physiol. 2004;286(4):R608-23.
[14]
Lu H, Forbes RA, Verma A. Hypoxia-inducible factor 1 activation by aerobic glycolysis implicates the Warburg effect in carcinogenesis. J Biol Chem. 2002;277(26):23111-5.
[15]
Minchenko O, Opentanova I, Caro J. Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo. FEBS Lett. 2003;554(3):264-70.
[16]
Navarro-Sabate A, Manzano A, Riera L, Rosa JL, Ventura F, Bartrons R. The human ubiquitous 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene (PFKFB3): promoter characterization and genomic structure. Gene. 2001;264(1):131-8.
[17]
Hirata T, Kato M, Okamura N, Fukasawa M, Sakakibara R. xpression of human placental-type 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatase in various cells and cell lines. Biochem Biophys Res Commun. 1998;242(3):680-4.
[18]
Chesney J, Mitchell R, Benigni F, Bacher M, Spiegel L, Al-Abed Y, Han JH, Metz C, Bucala R. An inducible gene product for 6-phosphofructo-2-kinase with an AU-rich instability element: role in tumor cell glycolysis and the Warburg effect. Proc Natl Acad Sci U S A. 1999;96(6):3047-52.
[19]
Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, Makita Z, Mitchell R, Bucala R. High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res. 2002;62(20):5881-7.
[20]
Watanabe F, Sakai A, Furuya E. Novel isoforms of rat brain fructose 6-phosphate 2-kinase/fructose 2,6-bisphosphatase are generated by tissue-specific alternative splicing. J Neurochem. 1997;69(1):1-9.
[21]
Kessler R, Eschrich K. Splice isoforms of ubiquitous 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase in human brain. Brain Res Mol Brain Res. 2001;87(2):190-5.
[22]
Wu C, Okar DA, Newgard CB, Lange AJ. Overexpression of 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase in mouse liver lowers blood glucose by suppressing hepatic glucose production. J Clin Invest. 2001;107(1):91-8.
[23]
Duran J, Navarro-Sabate A, Pujol A, Perales JC, Manzano A, Obach M, Gomez M, Bartrons R. Overexpression of ubiquitous 6-phosphofructo-2-kinase in the liver of transgenic mice results in weight gain. Biochem Biophys Res Commun. 2008;365(2):291-7.
[24]
Minchenko AG, Stevens MJ, White L, Abatan OI, Komjati K, Pacher P, Szabo C, Obrosova IG. Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(ADP-ribose) polymerase activation. FASEB J. 2003;17(11):1514-6.
[25]
Obrosova IG, Minchenko AG, Frank RN, Seigel GM, Zsengeller Z, Pacher P, Stevens MJ, Szabo C. Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression. Int J Mol Med. 2004;14(1):55-64.
[26]
Drogat B, Auguste P, Nguyen DT, Bouchecareilh M, Pineau R, Nalbantoglu J, Kaufman RJ, Chevet E, Bikfalvi A, Moenner M. IRE1 signaling is essential for ischemia-induced vascular endothelial growth factor-A expression and contributes to angiogenesis and tumor growth in vivo. Cancer Res. 2007;67(14):6700-7.
[27]
Riera L, Manzano A, Navarro-Sabate A, Perales JC, Bartrons R. Insulin induces PFKFB3 gene expression in HT29 human colon adenocarcinoma cells. Biochim Biophys Acta. 2002;1589(2):89-92.
[28]
Duran J, Gomez M, Navarro-Sabate A, Riera-Sans L, Obach M, Manzano A, Perales JC, Bartrons R. Characterization of a new liver- and kidney-specific pfkfb3 isozyme that is downregulated by cell proliferation and dedifferentiation. Biochem Biophys Res Commun. 2008;367(4):748-54.
[29]
Wu C, Okar DA, Kang J, Lange AJ. Reduction of hepatic glucose production as a therapeutic target in the treatment of diabetes. Curr Drug Targets Immune Endocr Metabol Disord. 2005;5(1):51-9.
